Tag: Zanidatamab
China’s NMPA Accepts BLA for Zanidatamab in HER2+ Biliary Tract Cancer
China’s NMPA Accepts BLA for Zanidatamab in HER2+ Biliary Tract CancerThe National Medical Products Administration (NMPA) in China has approved the biologics license application (BLA) for zanidatamab for the treatment of patients with HER2-positive...
